Research progress in the inhibition of breast cancer metastasis by co-delivering paclitaxel nanodrugs

VernacularTitle:共递送紫杉醇的纳米药物抑制乳腺癌转移的研究进展
Author: Cuicui ZHAO ¹ ; Chuangui ZHANG
Author Information

1. 天津医科大学肿瘤医院特需病房，国家恶性肿瘤临床医学研究中心，天津市"肿瘤防治"重点实验室，天津市恶性肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室，天津　300060
Keywords: Paclitaxel; Breast cancer; Nanomedicine; Co-delivery
From: International Journal of Biomedical Engineering 2022;45(4):345-349
CountryChina
Language:Chinese
Abstract: Breast cancer is the malignancy with the highest number of new cases worldwide and is the leading cause of cancer-related deaths in women. More than 90% of breast cancer-related deaths are related to its metastasis. Paclitaxel, one of the most commonly used chemotherapeutic agents for the treatment of breast cancer, is an effective means of inhibiting breast cancer metastasis. To overcome the adverse effects of paclitaxel's hydrophobicity and its co-solvent, its nano-drugs have been a hot research topic. Some nanomedicines delivering paclitaxel have been used in clinical practice and have shown satisfactory efficacy and good tolerability. In this review, the research progress on the inhibition of breast cancer metastasis by co-delivered paclitaxel nanomedicines was summarized with the aim of providing a reference for their anti-breast cancer metastasis research.